Chronic Lymphocytic Leukemia | Topics

Continuous/Limited Venetoclax Plus Rituximab Yields Robust, Long-Lasting 5-Year Response in Relapsed CLL
November 23, 2021

Patients with relapsed chronic lymphocytic leukemia who were treated with either limited or continuous venetoclax and rituximab experienced improved responses during a 5-year follow-up.

Frontline Treatment With Acalabrutinib, Venetoclax, and Obinutuzumab Highly Active, Tolerable for Chronic Lymphocytic Leukemia
November 01, 2021

A phase 2 study found that acalabrutinib monotherapy followed by treatment with venetoclax and obinutuzumab in the frontline setting was highly active and tolerable for patients with previously untreated chronic lymphocytic leukemia despite not meeting the primary end point.

TP53 and IGHV Continue to Demonstrate Utility as Predictive Markers of Response in CLL
October 23, 2021

In a debate, experts discuss the importance of IGHV and TP53 mutational status in predicting response to novel therapies in chronic lymphocytic leukemia.

Ibrutinib for CLL Leads to Higher Risk of Certain Cardiovascular Events
October 08, 2021

Ibrutinib for treating patients with chronic lymphocytic leukemia increased the risk of atrial fibrillation, bleeding, and heart failure in results of a cohort study.

New Targets Open Possibilities for Novel Antibodies and Cellular Therapies in CLL
October 01, 2021

As more novel therapeutic targets are discovered in patients with chronic lymphocytic leukemia, the more possibilities are presented in terms of treatment with targeted agents, small molecules, and cellular therapies.

Pirtobrutinib Yields Promising Responses in Previously Treated CLL/SLL
September 13, 2021

Patients with previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma appeared to benefit from treatment with pirtobrutinib.

Pirtobrutinib Demonstrates Strong Response Rates for Previously Treated CLL/SLL
September 11, 2021

Strong response rates were observed with pirtobrutinib across dose levels to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma ion a phase 1/2 study.

Pretreatment With Ibrutinib Reduced Obinutuzumab-Induced Cytokine Secretion and Infusion-Related Reactions in CLL/SLL
August 17, 2021

Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma were pretreated with ibrutinib saw a reduction in obinutuzumab-induced infusion-related reactions as well as cytokines and chemokines.

Acalabrutinib/Obinutuzumab Prolongs PFS vs Ibrutinib and Venetoclax Combos in CLL, Meta-Analysis Says
August 12, 2021

A systemic review and network meta-analysis investigated 3 trials and determined that acalabrutinib/obinutuzumab up front prolongs progression-free survival for patients with chronic lymphocytic leukemia vs other regimens.

SEQUOIA Trial Meets Primary PFS End Point Improvement With Frontline Zanubrutinib for CLL
August 02, 2021

The SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab for patients with treatment-naïve chronic lymphocytic leukemia demonstrated superior progression-free survival results with the BTK inhibitor.